Barclays’s West Pharmaceutical WST Stock Holding History

Barclays’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5M	Hold	50,000	–	–	﹤0.01%	1329
2025 Q4	$13.8M	Buy	+50,000	New	+$13.7M	﹤0.01%	1459
2025 Q1	–	Sell	-215,000	Closed	-$70.4M	–	5604
2024 Q4	$70.4M	Buy	215,000 +60,900	+40%	+$19.2M	0.02%	533
2024 Q3	$46.3M	Buy	+154,100	New	+$47.2M	0.01%	700

Other funds holding WST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's WST Position: Q1 2026 in Review

Barclays increased its West Pharmaceutical (WST) stake by 146% in Q1 2026, buying an estimated $51.5M and bringing the position to 349,104 shares worth $87.5M. The position accounts for 0.02% of the portfolio, ranked #537.

Barclays first reported a position in WST in Q2 2013 and has held it in 52 quarters since. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Barclays held 349,104 shares of West Pharmaceutical worth $87.5M as of Q1 2026.
Barclays bought 206,919 West Pharmaceutical shares in Q1 2026, an estimated $51.5M.
West Pharmaceutical made up 0.02% of Barclays's portfolio in Q1 2026, its #537 holding.
Barclays first reported a position in West Pharmaceutical in Q2 2013 and has held it in 52 quarters since.
753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.